How to buy Sorrento Therapeutics (SRNE) stock

Sorrento Therapeutics, Inc is a biotechnology business based in the US. Sorrento Therapeutics shares (SRNE) are listed on the NASDAQ and all prices are listed in US Dollars. Sorrento Therapeutics employs 502 staff and has a trailing 12-month revenue of around 0.00.

Sorrento Therapeutics stock price (NASDAQ: SRNE)

Use our graph to track the performance of SRNE stocks over time.

Sorrento Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-22.

Latest market close	$8.11
52-week range	$5.77 - $19.39
50-day moving average	$8.87
200-day moving average	$9.19
Wall St. target price	$28.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.40

Buy Sorrento Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Sorrento Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Sorrento Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sorrento Therapeutics price performance over time

Historical closes compared with the close of $8.11 from 2021-06-04

1 week (2021-07-16)	N/A
1 month (2021-06-25)	-17.75%
3 months (2021-04-27)	-7.95%
6 months (2021-01-23)	N/A

1 year (2020-07-23)	N/A
2 years (2019-07-23)	N/A
3 years (2018-07-23)	N/A
5 years (2016-07-23)	N/A

Sorrento Therapeutics financials

Revenue TTM	$46.5 million
Gross profit TTM	$-81,294,000
Return on assets TTM	-25.62%
Return on equity TTM	-172.14%
Profit margin	0%
Book value	$0.83
Market capitalisation	$2.6 billion

TTM: trailing 12 months

Shorting Sorrento Therapeutics shares

There are currently 50.4 million Sorrento Therapeutics shares held short by investors – that's known as Sorrento Therapeutics's "short interest". This figure is 0.9% down from 50.8 million last month.

There are a few different ways that this level of interest in shorting Sorrento Therapeutics shares can be evaluated.

Sorrento Therapeutics's "short interest ratio" (SIR)

Sorrento Therapeutics's "short interest ratio" (SIR) is the quantity of Sorrento Therapeutics shares currently shorted divided by the average quantity of Sorrento Therapeutics shares traded daily (recently around 8.0 million). Sorrento Therapeutics's SIR currently stands at 6.32. In other words for every 100,000 Sorrento Therapeutics shares traded daily on the market, roughly 6320 shares are currently held short.

However Sorrento Therapeutics's short interest can also be evaluated against the total number of Sorrento Therapeutics shares, or, against the total number of tradable Sorrento Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sorrento Therapeutics's short interest could be expressed as 0.17% of the outstanding shares (for every 100,000 Sorrento Therapeutics shares in existence, roughly 170 shares are currently held short) or 0.1958% of the tradable shares (for every 100,000 tradable Sorrento Therapeutics shares, roughly 196 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Sorrento Therapeutics.

Find out more about how you can short Sorrento Therapeutics stock.

Sorrento Therapeutics share dividends

We're not expecting Sorrento Therapeutics to pay a dividend over the next 12 months.

Have Sorrento Therapeutics's shares ever split?

Sorrento Therapeutics's shares were split on a 1:25 basis on 31 July 2013. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sorrento Therapeutics shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Sorrento Therapeutics shares which in turn could have impacted Sorrento Therapeutics's share price.

Sorrento Therapeutics share price volatility

Over the last 12 months, Sorrento Therapeutics's shares have ranged in value from as little as $5.77 up to $19.39. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sorrento Therapeutics's is 2.3683. This would suggest that Sorrento Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Sorrento Therapeutics overview

Sorrento Therapeutics, Inc. , a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host diseases. The company also develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, it engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions.

Frequently asked questions

What percentage of Sorrento Therapeutics is owned by insiders or institutions?
Currently 9.3% of Sorrento Therapeutics shares are held by insiders and 26.445% by institutions. How many people work for Sorrento Therapeutics?
Latest data suggests 502 work at Sorrento Therapeutics. When does the fiscal year end for Sorrento Therapeutics?
Sorrento Therapeutics's fiscal year ends in December. Where is Sorrento Therapeutics based?
Sorrento Therapeutics's address is: 4955 Directors Place, San Diego, CA, United States, 92121 What is Sorrento Therapeutics's ISIN number?
Sorrento Therapeutics's international securities identification number is: US83587F2020 What is Sorrento Therapeutics's CUSIP number?
Sorrento Therapeutics's Committee on Uniform Securities Identification Procedures number is: 74838K108